MARKET

ICCC

ICCC

Immucell
NASDAQ
5.02
-0.03
-0.59%
After Hours: 5.02 -0.1 -1.95% 16:00 04/19 EDT
OPEN
5.05
PREV CLOSE
5.05
HIGH
5.12
LOW
5.01
VOLUME
3.19K
TURNOVER
0
52 WEEK HIGH
6.05
52 WEEK LOW
4.260
MARKET CAP
38.91M
P/E (TTM)
-6.7355
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ICCC last week (0408-0412)?
Weekly Report · 5d ago
IMMUCELL CORP - ENTERED INTO AT MARKET OFFERING AGREEMENT WITH CRAIG-HALLUM CAPITAL GROUP LLC
Reuters · 04/09 21:20
IMMUCELL CORP - FIRST AMENDMENT, AMENDS FAME LOAN DEAL TO REMOVE ANY RESTRICTIONS ON CO’S ABILITY TO ISSUE EQUITY SECURITIES, PERMITTING SALES
Reuters · 04/09 21:20
IMMUCELL CORP -PURSUANT TO AGREEMENT, CO MAY OFFER AND SELL, FROM TIME TO TIME, UP TO $11 MLN OF SHARES OF ITS COMMON STOCK
Reuters · 04/09 21:20
IMMUCELL CORP - ON APRIL 8, CO ENTERED INTO AMENDMENT TO CO’S ECONOMIC RECOVERY LOAN PROGRAM LOAN AGREEMENT, DATED JULY 17, 2023
Reuters · 04/09 21:20
ImmuCell reports preliminary Q1 sales, stock climbs 7%
ImmuCell reports preliminary Q1 2024 sales jumped 111% year-over-year to $7.3M. The animal health company's stock climbs 7% in post-market trading. The company expects a response from the FDA in May for its cow health product Re-Train.
Seeking Alpha · 04/09 20:47
12 Health Care Stocks Moving In Tuesday's After-Market Session
Jaguar Health (NASDAQ:JAGX) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million. ATyr Pharma shares rose 10.45% and Corvus Pharma shares increased by 7.36%. Apyx Medical shares declined by 6.1% during the session.
Benzinga · 04/09 20:31
ImmuCell Reports Preliminary, Unaudited Sales Results For Q1 2024 Of $7.3M, Up 111% Y/Y
Benzinga · 04/09 20:09
More
About ICCC
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing Immediate Immunity against each of the three causes of calf scours (E. coli, coronavirus, and rotavirus).

Webull offers ImmuCell Corp stock information, including NASDAQ: ICCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICCC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ICCC stock methods without spending real money on the virtual paper trading platform.